Generation of CD3+CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells

International Journal of Hematology

Volumn 77, Issue 2, 2003, Pages 175-179

  Hongeng, Suradej ^a   Petvises, Sawang ^a   Worapongpaiboon, Surapon ^a   Rerkamnuaychoke, Busaba ^a   Pakakasama, Samart ^a   Jootar, Saengsuree ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

CD3+CD56+ cells; Cytotoxicity; Immunotherapy; Pediatric cancers

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CYTOKINE; GAMMA INTERFERON; LACTATE DEHYDROGENASE; RECOMBINANT INTERLEUKIN 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MALE; NATURAL KILLER CELL; OSTEOSARCOMA; REMISSION; CELL CULTURE; CULTURE TECHNIQUE; CYTOTOXICITY TEST; DRUG EFFECT; IMMUNOLOGY; KILLER CELL; NEOPLASM; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ANTIGENS, CD3; ANTIGENS, CD56; CELL CULTURE TECHNIQUES; CHILD; CHILD, PRESCHOOL; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; KILLER CELLS; MALE; NEOPLASMS; REMISSION INDUCTION; TUMOR CELLS, CULTURED;

EID: 0038312166     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983217     Document Type: Article

References (20)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5-27.
2. Rosenberg SA, Spiess PS, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318-1321.
3. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and IL-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319:1676-1680.
4. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:622-632.
5. Faber LM, van Luxemberg-Heijs SAP, Willemze R, Falkenburg JHF. Generation of leukemia-reactive cytotoxic T-lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med. 1992;176:1283-1289.
6. Oettel KR, Wesly OH, Albertini MR, et al. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome (Ph1+) human leukemia cell lines can also recognize Ph1- cells from the same patient. Blood. 1994;11:3390-3402.
7. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21:1673-1679.
8. Schmidt-Wolf IG, Lefterova P, Johnston V, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol. 1995;169:85-90.
9. Scheffold C, Brandt K, Johnston V, et al. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant. 1995;15:33-39.
10. Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med. 1986;164:351-356.
11. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD 16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136:4480-4486.
12. + cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol. 1991;136:486-495.
13. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687-1696.
14. + cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy. Haematologica. 2000;104:72-79.
15. + cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998;92:3318-3327.
16. + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother. 2000;49:335-345.
17. + killer cells. Blood. 1995;86:3493-3499.
18. Wood GW, Holladay FP, Turner T, Wang YY, Chiga M. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulation lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol. 2000;48:113-120.
19. Leemhuis T, Wells S, Horn P, et al. Autologous cytokine-induced killer cell for the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma [abstract]. Blood. 2000;96:839a.
20. + natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood. 2001;97:2923-2931.